Cobraxane nanoparticle (paclitaxel) / Abeona Therap - LARVOL DELTA

Updates in immunotherapy for head and neck cancer (iVoox) - "In this podcast we'll be covering some of the latest updates in immunotherapy for head and neck cancer. Ezra Cohen, MD, FRCPSC, FASCO, Moores Cancer Center at UC San Diego Health, San Diego, CA, discusses the clinical activity of petosemtamab, a bispecific antibody targeting EGFR and LGR5, in patients with head and neck squamous carcinoma (HNSCC)....Ari Rosenberg, MD...describes the trial design of the Phase II DEPEND trial (NCT03944915), which assessed neoadjuvant nivolumab, paclitaxel, and carboplatin followed by response-stratified chemoradiation (CRT) in locoregionally advanced HPV-negative HNSCC."

Audio

Response-stratified chemoradiation enhances deep response rates in HNSCC (YouTube) - "Ari Rosenberg, MD...discusses findings from the Phase II DEPEND trial (NCT03944915), which assessed neoadjuvant nivolumab, paclitaxel, and carboplatin followed by response-stratified chemoradiation in patients with advanced HPV-negative head and neck squamous cell carcinoma (HNSCC). Nivolumab-based neoadjuvant chemoimmunotherapy resulted in deep responses, and response-adapted CRT led to promising survival. PD-1 status was additionally associated with deep responses."

Interview • Video

A Phase IB study of the combination SM08502 CLK inhibitor and weekly paclitaxel in recurrent endometrial carcinoma (NRG Winter 2023)

Update on Treatment Tactics in ALK/ROS/RET-Rearranged NSCLC (MedPageToday) - "Sanjay Popat, MBBS, PhD....Pralsetinib is an investigational RET inhibitor with greater selectivity and potency than the previous multikinase inhibitors and selectively targets RET fusions and mutations. In the phase I/II ARROW study, pralsetinib demonstrated an overall response rate of 79% and substantial anti-tumor activity in patients with RET fusion-positive NSCLC....The primary endpoint is PFS compared to investigator's choice of SOC treatment. The target sample size is 226, which has been determined on the basis of the assumption to detect the HR 0.57 for pralsetinib versus standard chemotherapy."

Media quote

World Lung Cancer Day With Beth Sandy, MSN, CRNP, and Corey Langer, MD (Oncology Data Advisor) - "...Dr. Langer discussed the improvements in survival that have occurred in recent years due to the development of novel therapies, groundbreaking developments in the fields of immunotherapy and targeted therapy, and exciting advances that lay on the horizon for patients with lung cancer in the coming years."

Interview • Video

Advanced NanoTherapies closes Series A funding round (Cardiovascular news) - "'Sirolimus and paclitaxel are both proven drugs in the vascular space, each with unique benefits, limitations, and mechanisms of action,' commented Mehdi Shishehbor...'Pre-clinical data have shown that using both drugs in combination results in higher antiproliferative potency at lower doses than using each drug independently. The synergistic effects of eluting them simultaneously over long periods may be the key to sustaining patency following interventions.'"

Media quote

Paclitaxel-Coated Devices For Patients With Peripheral Artery Disease (EMJ Reviews) - "Eric Secemsky...highlighted the objective of the study: 'Our goal is to give patients the most durable treatment possible that will keep them out of the hospital and living their lives. Patients with PAD tend to be of lower socioeconomic status, more likely to be underserved minority populations, and often need to travel long distances or take time off work to seek treatment.'"

Media quote

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy (TCTMD) - "'These long-term results from this large, international, real-world study add to the growing body of evidence that demonstrates the safety, effectiveness, consistency, and durability of the IN.PACT Admiral DCB for the treatment of femoropopliteal lesions,' write researchers led by Thomas Zeller, MD, PhD..."

Media quote

No Increase in Long-Term Mortality Seen With Peripheral Drug-Coated Devices (PracticeUpdate) - "Eric A. Secemsky, M.D....presented the most contemporary follow-up data for more than 70,000 patients aged 66 years or older treated with DCDs. The study included all Medicare fee-for-service beneficiaries who underwent femoropopliteal artery revascularization with either a DCD (drug-eluting stent or drug-coated balloon) or a non-DCD (NDCD; bare metal stent or percutaneous transluminal angioplasty). Of 168,553 patients, 41.9 percent were treated with a DCD; the median follow-up was 3.52 years."

SAFE PAD: Paclitaxel-coated devices noninferior to uncoated devices for mortality (Healio) - "'If we did a randomized control trial powered for 4- to 5-year mortality, we'd need between 20,000 and 40,000 patients, which would be by far and away the largest peripheral study ever, and also have to exclude everybody already treated with paclitaxel-coated devices, which had been the standard of care up to that point,' Secemsky said."

Media quote

SAFE-PAD: No Difference in Mortality with Paclitaxel-Coated Devices Up to 6 Years Out (Practical Cardiology) - "'Our goal is to give patients the most durable treatment possible that will keep them out of the hospital and living their lives. Patients with PAD tend to be of lower socioeconomic status, more likely to be underserved minority populations and often need to travel long distances or take time off work to seek treatment,' said study presenter Eric Secemsky, MD..."

Media quote

My Treatment Approach: Endometrial Carcinoma - Episode 3: Treatment Options for Advanced Stage Relapsed Endometrial Carcinoma (OncLive) - "Bradley Monk, MD, FACOG, FACS: The molecular signature matters. Essentially, every second-line patient, including those who got adjuvant therapy like this 1, needs pembrolizumab in the second line. The only question is, do they need lenvatinib when pembrolizumab is not going to work very well? David O'Malley, MD: Brad, I've got to interrupt you. She's platinum sensitive. She's recurred 8 months."

Video

Low-Dose Chemotherapy With Immunotherapy Shows Efficacy in UC (Targeted Oncology) - "In an interview with Targeted Oncology™, Rhonda L. Bitting, MD, discussed the efficacy results and key takeaways of a study investigating low-dose paclitaxel plus pembrolizumab in patients with platinum-refractory UC....Bitting: When urothelial carcinoma is, it is a life-threatening disease, and we currently have a couple of options to treat folks who present after progression on platinum chemotherapy."

Interview

Managing Acquired Resistance in EGFR-Mutated Non–Small Cell Lung Cancer (ASCO Daily News) - "The management of acquired resistance to EGFR-mutated non-small cell lung cancer (NSCLC) has undergone significant change since osimertinib was approved by the U.S. Food and Drug Administration (FDA) for first-line treatment of the most common EGFR-activating mutations, EGFR E19del and L858R, in December 2020....In addition to examining plasma circulating tumor DNA for resistance mechanisms, it is also important to consider tissue biopsy to rule out small cell/histologic transformation or detect actionable alterations that may not be detected in plasma."

Online posting • Regulatory

PET/CT based imaging biomarkers for response prediction of stage IV NSCLC treated with paclitaxel–carboplatin–bevacizumab with or without nitroglycerin (ELCC 2016) - P2, N=60; NCT01171170; “There were more PET-based responders in week 3 than CT-based responders…PET showed a high sensitivity whereas CT showed a high specificity…PET parameters (max and peak SUV) reached a significant AUC to predict RECIST analysis.”

Biomarker • Biosimilar • Non Small Cell Lung Cancer • Oncology

Bevacizumab-improved distribution of paclitaxel in ovarian cancer xenografts potentiates antitumor efficacy (AACR 2016) - "Bevacizumab decreased tumor vessel number/size compared to vehicle treated mice, but potentiated the antitumor activity of paclitaxel in both models."

Preclinical • Biosimilar • Oncology • Ovarian Cancer

Debu Tripathy, MD, on the future of triple negative breast cancer treatment (Cancer Network) - "So, there are some studies underway now to look at targeted therapies for these patients or maybe non targeted therapies, for example, the immunoconjugates sacituzumab govitecan, which has some activity in refractory triple negative breast cancer could be used in these patients, or even cytotoxic therapy, or maybe we can just use capecitabine again, but use in a more focused way....In metastatic triple negative breast cancer, the outcomes are still very poor unfortunately. Patients, some patients do have long responses to chemotherapy and immunotherapy....Sacituzumab govitecan is one that's furthest along and is likely to be approved first because we already have data, uncontrolled data, right, phase II data showing activity in that disease with a randomized trial called the ASCENT trial in progress and we'll report soon."

Video